Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 2Phase NA 1Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Thoracic 6Other hematologic neoplasm 6Head & Neck 5Gastrointestinal 5Sarcoma 4Plasma cell 4Gynecologic 3NET 2Myeloid 2Genitourinary 2Endocrine 2CNS 2Other solid neoplasm 1Other neoplasm 1Dermatologic 1

Conditions

Prostatic Neoplasms 383Carcinoma, Renal Cell 210Urinary Bladder Neoplasms 117Carcinoma, Non-Small-Cell Lung 99Melanoma 78Kidney Neoplasms 74Carcinoma, Transitional Cell 73Neoplasm Metastasis 72Ovarian Neoplasms 71Breast Neoplasms 69Neoplasms 64Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 50Stomach Neoplasms 49Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 39Lung Neoplasms 35Esophageal Neoplasms 32Non-Muscle Invasive Bladder Neoplasms 31Endometrial Neoplasms 30Carcinoma, Hepatocellular 29Sarcoma 28Small Cell Lung Carcinoma 25Head and Neck Neoplasms 25Colonic Neoplasms 19Wilms Tumor 15Metastatic Castration-resistant Prostate Cancer 14Glioblastoma 14Carcinoma, Merkel Cell 14

Interventions

pembrolizumab 1enzalutamide 1Taxes 1Pemetrexed 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × Genitourinary × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡